Clinical trial

A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals

NCT05208125

Study summary

ClinicalTrials.gov

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BIOLOGICAL · Unmapped registry intervention ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS). Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Normal saline solution Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-03-30

PhasePHASE1

Conditions

HIV Infectionverified · MONDO: HIV infectious disease

Interventions

ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).BIOLOGICAL

Normal saline solutionOTHER

Sponsors & collaborators

IrsiCaixalead sponsor

José Moltó Marhuenda, PhD, MDcollaborator

Beatriz Mothe Pujadas PhD,MDcollaborator

Susana Benet Garrabé, PhD,MDcollaborator

Lucía Bailón Álvarez, MDcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05208125 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.